MEMORY EXPRESS ZERTIFIKAT - PFIZER INC/ELI LILLY & CO | Market Closed - Deutsche Boerse AG 11:20:46 2024-05-17 EDT | ||
| 76.85 EUR | -0.68% |
|
| Current month | +16.58% | ||
| 1 month | +18.61% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 76.85 | -0.68% |
| 24-05-16 | 77.38 | -0.68% |
| 24-05-15 | 77.91 | +1.62% |
| 24-05-14 | 76.67 | -0.84% |
| 24-05-13 | 77.32 | +2.86% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 11:20 am
More quotesStatic data
| Product type | Other Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PF99LH |
| ISIN | DE000PF99LH6 |
| Date issued | 2022-03-04 |
| Strike | 250 $ |
| Maturity | 2027-03-01 (1018 Days) |
| Parity | 0.25 : 1 |
| Emission price | 100 € |
| Emission volume | N/A |
| Settlement | both |
| Currency | EUR |
Technical Indicators
| Highest since issue | 107.6 € |
|---|---|
| Lowest since issue | 63.04 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
770
USD
Average target price
850.4
USD
Spread / Average Target
+10.44%
- Stock Market
- Certificates
- Certificat
